Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs Recursion Pharmaceuticals Inc — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $36, while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Roundhill NVDA WeeklyPay ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NVDW | RXRX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $53.42 | $6.79 |
52-Week Low | $31.88 | $2.84 |
Market Cap | — | $1.53B |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $35.20, down 1.1% today, with technical indicators showing bearish momentum as moving averages signal strong selling pressure. The ETF maintains an active dividend distribution schedule with multiple payouts in recent months, though key valuation metrics remain unavailable for analysis. Current price action sits near support at $35 with resistance forming at $36.
The outlook remains cautious given the bearish technical signals and lack of fundamental data transparency. Investment opportunity exists primarily through the dividend income stream, though payout volatility presents risk. Market sentiment appears mixed with Seeking Alpha highlighting the ETF's role as a Nvidia hedge with variable yield characteristics.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
